A Vaccine Built From One Patient’s Tumor
Most vaccines are manufactured in bulk and shipped to millions of people who receive the identical product. An individualized neoantigen mRNA cancer vaccine inverts that logic entirely: the starting material is a single patient’s surgically removed tumor, and the finished therapy is intended for that person alone. The approach that has drawn the most attention is intismeran autogene, also known as intismeran, V940, or mRNA-4157, developed by Merck and Moderna. Understanding how it is made explains why it behaves so differently from anything off the shelf.
From Resected Tumor to Mutation List
The process begins in the operating room. Patients eligible for this therapy have had their tumor completely resected, meaning the cancer was surgically removed. A sample of that removed tissue becomes the raw input for a sequencing pipeline. Investigators sequence the tumor’s DNA and compare what they find against the patient’s normal genetic material. The goal of that comparison is to isolate the mutations that exist only in the cancer, the errors that accumulated as the tumor grew.
Among those mutations, the most useful are the ones that change the proteins a cancer cell displays. When a mutation alters a protein, fragments of it can be presented on the cell surface in a way immune cells can inspect. Those recognizable fragments are called neoantigens, and they are the target of the entire enterprise. Because they arise from the patient’s own tumor, they are not shared across a population; each tumor carries its own set.
Choosing Up to 34 Targets
Not every mutation makes a good target. Selection requires sorting through the sequencing data to find neoantigens with the best chance of provoking a strong, specific immune response. From that analysis, the manufacturers select up to 34 neoantigens to encode into the therapy. That upper limit defines the product’s scope: a compact, patient-specific list of the tumor’s most exploitable vulnerabilities.
Once the list is set, the manufacturing switches from discovery to production. The selected neoantigen sequences are encoded into messenger RNA, the same molecular instructions cells use to build proteins. That mRNA is then formulated into a bespoke therapy manufactured for that one patient. The result is not a generic drug pulled from a shelf but a made-to-order batch whose contents are determined by a single person’s tumor.
The Wanted Poster Analogy
A useful way to picture the mechanism is a personalized wanted poster. The vaccine does not attack the cancer directly. Instead, it delivers the mRNA instructions into the patient’s body, where cells read them and produce the selected neoantigen proteins. Those proteins act as the images on the poster, showing the immune system exactly what the enemy looks like. Immune cells encounter this material, learn to recognize the neoantigens as targets, and are trained to hunt down cells displaying them. Because the targets were drawn from the patient’s own tumor, the training is specific to that cancer rather than to cancer in general.
Why a Checkpoint Inhibitor Complements It
Teaching the immune system to recognize a target is only half the problem; tumors also actively suppress immune attacks. That is where pembrolizumab, sold as KEYTRUDA, comes in. It is an anti-PD-1 immunotherapy, a checkpoint inhibitor, which works by interfering with a brake that cancers use to restrain immune cells. In the treatment regimen studied, patients received intismeran alongside pembrolizumab. The pairing is complementary: the individualized mRNA vaccine supplies the specificity, directing the immune response at the tumor’s unique neoantigens, while the checkpoint inhibitor helps loosen the restraints that would otherwise blunt that response.
The Phase 3 Result That Put the Approach on the Map
The manufacturing model gained prominence after Merck and Moderna announced top-line Phase 3 results on 19 August 2026. The trial, INTerpath-001 (NCT05933577), was a randomized, double-blind, global Phase 3 study in 1,137 patients with completely resected stage IIB to IV cutaneous melanoma who had received no prior systemic therapy. Participants were randomized 2:1: 758 received intismeran 1 mg every three weeks for up to nine doses plus pembrolizumab 400 mg every six weeks for about one year, and 379 received pembrolizumab alone.
The primary endpoint, recurrence-free survival, was met. The key secondary endpoint, distant-metastasis-free survival, was also met. Both were described as statistically significant and clinically meaningful. Safety was consistent with prior studies, with no new safety signals; most side effects were grade 1-2, such as injection-site reactions, fatigue, and chills, and grade 3 immune-related adverse events occurred in 10.6% of the combination arm versus 12% in the pembrolizumab-alone arm. Prof Georgina Long of the Melanoma Institute Australia called it a “landmark moment for adjuvant melanoma treatment” and noted it was the “first Phase 3 study to show that intismeran… can reduce the risk of recurrence or death.” An earlier Phase 2b trial, KEYNOTE-942, which enrolled 157 patients with stage IIIB to IV disease, had reported an RFS hazard ratio of 0.51 and a DMFS hazard ratio of 0.411, but those are Phase 2b findings and should not be read as Phase 3 results.
What Remains Unknown
These are top-line Phase 3 results only. Detailed data are expected to be presented at an upcoming medical meeting, and engagement with regulators on a filing is underway. Overall survival data remain under follow-up and are not yet known, so it is not established whether the recurrence-free survival benefit will translate into longer lives. Intismeran remains investigational and is not yet approved for any use. The same therapy is being tested in nine additional Phase 2 and Phase 3 trials across non-small cell lung cancer, bladder cancer, renal cell carcinoma, pancreatic adenocarcinoma, and perioperative settings, but those studies have not reported outcomes here. Anyone weighing this approach should talk to their own doctor about whether a clinical trial is appropriate for their situation.
